© The Author 2006. Published by Oxford University Press.
ARTICLE |
Use of Three-Dimensional Tissue Cultures to Model Extravascular Transport and Predict In Vivo Activity of Hypoxia-Targeted Anticancer Drugs
Affiliations of authors: Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand (KOH, FBP, MPH, WAD, WRW); Department of Physiology, University of Arizona, Tucson, AZ (TWS, RH); Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA (JMB); Department of Radiation Oncology, Duke University Medical Center, Durham, NC (MWD)
Correspondence to: Kevin O. Hicks, PhD, Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland, New Zealand (e-mail: k.hicks{at}auckland.ac.nz).
Background: Because of the inefficient vasculature of solid tumors, anticancer drugs must penetrate relatively long distances through the extravascular compartment. The requirement for such diffusion may limit their activity, especially that of hypoxia-targeted drugs. We tested whether a three-dimensional pharmacokinetic/pharmacodynamic (PK/PD) model based on a representative mapped tumor microvascular network could predict the therapeutic activity of anticancer drugs in mouse xenograft tumors. Methods: Diffusion coefficients of the hypoxia-activated anticancer drug tirapazamine (TPZ) and of 15 TPZ analogs were estimated by measuring their transport through HT29 colon cancer multicellular layers (MCLs). Anoxic cytotoxic potency (by clonogenic assay) and metabolism of the TPZ analogs were measured in HT29 cell suspensions, and their plasma pharmacokinetics was measured in CD-1 nude mice. This information was used to create a spatially resolved PK/PD model for the tumor microvascular network. Model predictions were compared with actual hypoxic cell kill as measured by clonogenic assays on HT29 xenograft tumors 18 hours after treatment with each TPZ analog. Results: Modeling TPZ transport in the tumor microvascular network showed substantial drug depletion in the most hypoxic regions, with predicted maximum cell kill of only 3 logs, compared with more than 10 logs if there were no transport impediment. A large range of tissue diffusion coefficients (0.027 x 10–6–1.87 x 10–6 cm2/s) was observed for the TPZ analogs. There was a strong correlation between model-predicted and measured hypoxic cell kill (R2 = 0.89) but a poor correlation when the model did not include extravascular transport (R2 = 0.32). Conclusions: Extravascular transport in tumors, and its consequences for tumor cell killing, can be predicted by measuring drug penetration through MCLs in vitro and modeling pharmacokinetics at each position in three-dimensional microvascular networks.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Respecting Cancer Drug Transportability: A Basis for Successful Lead Selection
- Edward A. Sausville
J Natl Cancer Inst 2006 98: 1098-1099.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  Q.-T. X. Le, J. Moon, M. Redman, S. K. Williamson, P. N. Lara Jr, Z. Goldberg, L. E. Gaspar, J. J. Crowley, D. F. Moore Jr, and D. R. Gandara Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222 J. Clin. Oncol., June 20, 2009; 27(18): 3014 - 3019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R Wilson, K. O Hicks, F. B Pruijn, and A. V Patterson Targeting Tumor Hypoxia with Prodrugs: Challenges and Opportunities Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 293 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Patterson, D. M. Ferry, S. J. Edmunds, Y. Gu, R. S. Singleton, K. Patel, S. M. Pullen, K. O. Hicks, S. P. Syddall, G. J. Atwell, et al. Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104 Clin. Cancer Res., July 1, 2007; 13(13): 3922 - 3932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Sausville Respecting cancer drug transportability: a basis for successful lead selection. J Natl Cancer Inst, August 16, 2006; 98(16): 1098 - 1099. [Full Text] [PDF]
|
|